Concepedia

Jill Nunez

JN

Statistics

Publications

10

Citations

494

H-Index

10

Active since

2007

Affiliations

Novartis (Switzerland)(Current)

Duke University

Novartis (United States)

Jill Nunez is an author at Novartis (Switzerland) specializing in drug discovery, medicinal chemistry, and pharmacy.

ORCID

Publications per year

2007–2020

10

Publications

10

Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer

George S. Tria, Tinya J. Abrams, Jason R. Baird et al. · Journal of Medicinal Chemistry · 2018 · 125 citations · Full text

, , +16

Regioselective Synthesis and Slow-Release Suzuki–Miyaura Cross-Coupling of MIDA Boronate-Functionalized Isoxazoles and Triazoles

Jill Nunez, Michael A. Dechantsreiter, Lawrence G. Hamann · The Journal of Organic Chemistry · 2011 · 76 citations

, , +15

Discovery of 2-Pyridylpyrimidines as the First Orally Bioavailable GPR39 Agonists

Stefan Peukert, Richard L. Hughes, Jill Nunez et al. · ACS Medicinal Chemistry Letters · 2014 · 54 citations · Full text

, , +16

Design, Synthesis, and Properties of a Potent Inhibitor of<i>Pseudomonas aeruginosa</i>Deacetylase LpxC

Grazia Piizzi, David T. Parker, Yunshan Peng et al. · Journal of Medicinal Chemistry · 2017 · 47 citations · Full text

, , +17

Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer

Heather Burks, Tinya J. Abrams, C.A. Kirby et al. · Journal of Medicinal Chemistry · 2017 · 42 citations · Full text

, , +17

1–5 of 10